Sensitization of AIDS-Kaposi's sarcoma cells to Apo-2 ligand-induced apoptosis by actinomycin D

Journal of Immunology

Volumn 162, Issue 9, 1999, Pages 5616-5623

  Mori, Shunsuke ^a   Murakami Mori, Kaoru ^a   Nakamura, Shuji ^b   Ashkenazi, Avi ^c   Bonavida, Benjamin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HUNTINGTON MEMORIAL HOSPITAL   (United States)

^c GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE INHIBITOR; DACTINOMYCIN; FAS ANTIGEN; PROTEIN BCL X; TUMOR NECROSIS FACTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; APOPTOSIS; ARTICLE; CELL SURVIVAL; CYTOTOXICITY; DOWN REGULATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; KAPOSI SARCOMA; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIZATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, CD95; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASPASES; CELL DEATH; DACTINOMYCIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FIBROBLASTS; HUMANS; LEUKOCYTES, MONONUCLEAR; LIGANDS; MEMBRANE GLYCOPROTEINS; RECOMBINANT PROTEINS; SARCOMA, KAPOSI; SOLUBILITY; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033136301     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Cosman, D. 1994. A family of ligands for the TNF receptor superfamily. Stem Cells 12:440.
2. Pitti, R. M., S. A. Marsters, S. Ruppert, C. J. Donahue, A. Moore, and A. Ashkenazi. 1996. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271:12687.
3. Wiley, S. R., K. Schooley, P. J. Smolak, W. S. Din, C. P. Huang, J. K. Nicholl, G. R. Sutherland, T. Davis Smith, C. Rauch, and C. A. Smith. 1995. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673.
4. Pan, G., K. O'Rourke, A. M. Chinnaiyan, R. Gentz, R. Ebner, J. Ni, and V. M. Dixit. 1997. The receptor for the cytotoxic ligand TRAIL. Science 276: 111.
5. Pan, G., J. Ni, Y.-F. Wei, G.-L. Yu, R. Gentz, and V. M. Dixit. 1997. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277:815.
6. Sheridan, J. P., S. A. Marsters, R. M. Pitti, A. Gurney, M. Skubatch, D. Baldwin, L. Ramarkrishnan, C. L. Gray, K. Baker, W. I. Wood, et al. 1997. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277:818.
7. Walczak, H., M. A. Degli-Eposti, R. S. Johnson, P. J. Smolak, J. Y. Waugh, N. Boiani, M. S. Timour, M. J. Gerhart, K. A. Schooley, C. A. Smith, et al. 1997. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 16:5386.
8. Wu, G. S., T. F. Bums, E. R. McDonald III, W. Jiang, R. Meng, I. D. Krantz, G. Kao, D. D. Can, J. Y. Zhou, R. Muschel, et al. 1997. Killer/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat. Genet. 17:141.
9. Chaudhary, P. M., M. Eby, A. Jasmin, A. Bookwalter, J. Murray, and L. Hood. 1997. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-κB pathway. Immunity 7:821.
10. Screaton, G. R., J. Mongkolsapaya, X.-N. Xu, A. E. Cowper, A. J. McMichael, and J. I. Bell. 1997. TRICK2, a new alternative spliced receptor that transduces the cytotoxic signal from TRAIL. Curr. Biol. 7:693.
11. MacFarlane, M., M. Ahmad, S. M. Srinivasula, T. Fernandes-Alnemri, G. M. Cohen, and E. S. Alnemri. 1997. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J. Biol. Chem. 272:25417.
12. Schneider, P., M. Thome, K. Bums, J.-L. Bodmer, K. Hofmann, T. Kataoka, N. Holler, and J. Tschopp. 1997. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-κB. Immunity 7:811.
13. Ashkenazi, A., and V. M. Dixit. 1998. Death receptors: signaling and modulation. Science 281:1305.
14. Degli-Esposti, M. A., P. J. Smolak, H. Walczak, J. Waugh, C.-P. Huang, R. F. DuBose, R. G. Goodwin, and C. A. Smith. 1997. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J. Exp. Med. 186:1163.
15. Mongkolsapaya, J., A. E. Cowper, X.-N. Xu, G. Morris, A. J. McMichael, J. I. Bell, and G. R. Screaton. 1998. Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL. J. Immunol. 160:3.
16. Marsters, S. A., J. P. Sheridan, R. M. Pitti, A. Huang, M. Skubatch, D. Baldwin, J. Yuan, A. Gurney, A. D. Goddard, P. Godowski, et al. 1997. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr. Biol. 7:1003.
17. Degli-Esposti, M. A., W. C. Dougall, P. J. Smolak, J. Y. Waugh, C. A. Smith, and R. G. Goodwin. 1997. The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 7:813.
18. Pan, G., J. Ni, G. Yu, Y.-F. Wei, and V. M. Dixit. 1998. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signaling. FEBS Lett. 424:41.
19. Dezube, B. J. 1996. Clinical presentation and natural history of AIDS-related Kaposi's sarcoma. Hematol. Oncol. Clin. North Am. 10:1023.
20. Ensoli, B., S. Nakamura, S. Z. Salahuddin, P. Biberfeld, B. Larsson, F. Beaver, F. Wong-Staal, and R. C. Gallo. 1989. AIDS Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. Science 243:223.
21. Ensoli, B., G. Barillari, and R. C. Gallo. 1991. Pathogenesis of AIDS-related Kaposi's sarcoma. Hematol. Oncol. Clin. North Am. 5:281.
22. Ensoli, B., P. Markham, V. Kao, G. Barillari, V. Fiorelli, R. Gendelman, M. Raffeld, G. Zon, and R. C. Gallo. 1994. Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis, and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor: a novel strategy for the therapy of KS. J. Clin. Invest. 94:1736.
23. Murakami-Mori, K., S. Mori, and S. Nakamura. 1998. Endogenous basic fibroblast growth factor is essential for cyclin E-CDK2 activity in multiple external cytokine-induced proliferation of AIDS-associated Kaposi's sarcoma cells: dual control of AIDS-associated Kaposi's sarcoma cell growth and cyclin E-CDK2 activity by endogenous and external signals. J. Immunol. 161:1694.
24. Nakamura, S., K. Murakami-Mori, N. Rao, H. A. Weich, and B. Rajeev. 1997. Vascular endothelial growth factor is a potent angiogenic factor in AIDS-associated Kaposi's sarcoma-derived spindle cells. J. Immunol. 158:4992.
25. Lee, F.-C., and R. T. Mitsuyasu. 1996. Chemotherapy of AIDS-related Kaposi's sarcoma. Hematol. Oncol. Clin. North Am. 10:1051.
26. Mori, S., K. Murakami-Mori, A. Jewett, S. Nakamura, and B. Bonavida. 1996. Resistance of AIDS-associated Kaposi's sarcoma cells co Fas-mediated apoptosis. Cancer Res. 56:1874.
27. Bohan Morris, C., R. Gendelman, A. J. Marrogi, M. Lu, J. M. Lockyer, W. Alperin-Lea, and B. Ensoli. 1996. Immunohistochemical detection of Bcl-2 in AIDS-associated and classical Kaposi's sarcoma. Am. J. Pathol. 148:1055.
28. L. Am. J. Pathol. 149:795.
29. + T cells. Science 242:426.
30. Murakami-Mori, K., T. Taga, T. Kishimoto, and S. Nakamura. 1995. AIDS-associated Kaposi's sarcoma (KS) cells express oncostatin M (OM)-specific receptor but not leukemia inhibitory factor/OM receptor or interleukin-6 receptor. J. Clin. Invest. 96:1319.
31. Bonavida, B., J. Safrit, H. Morimoto, Y. Mizutani, R. Uslu, N. Borsellino, P. Frost, J. Berek, A. Belldegrun, J. Zighelboim, C.-P. Ng, et al. 1997. Cross-resistance of tumor cells to chemotherapy and immunotherapy: approaches to reverse resistance and implications in gene therapy. Oncol. Rep. 4:201.
32. Berenbaum, M. C. 1981. Criteria for analyzing interactions between biologically active agents. Adv. Cancer Res. 35:269.
33. Thornberry, N. A., and Y. Lazebnik. 1998. Caspases: enemies within. Science 281:1312.
34. Marsters, S. A., R. M. Pitti, C. J. Donahue, S. Ruppert, K. D. Bauer, and A. Ashkenazi. 1996. Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. Curr. Biol. 6:750.
35. Mariani, S. M., B. Matiba, E. A. Armandola, and P. H. Krammer. 1997. Interleukin 1β-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells. J. Cell. Biol. 137:221.
36. Irmler, M., M. Thome, M. Hahne, P. Schneider, K. Hofmann, V. Steiner, J.-L. Bodmer, M. Schroter, K. Burns, C. Mattmann, et al. 1997. Inhibition of death receptor signals by cellular FLIP. Nature 338:190.
37. Hu, S., C. Vincenz, J. Ni, R. Gentz, and V. M. Dixit. 1997. I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1 and CD-95-induced apoptosis. J. Biol. Chem. 272:17255.
38. Thome, M., P. Schneider, K. Hofmann, H. Fickenscher, E. Meinl, F. Neipel, C. Mattman, K. Bruns, J. L. Bodmer, M. Schroter, et al. 1997. Viral FLICE inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 386:517.
39. Adams, J. M., and S. Cory. 1998. The Bcl-2 protein family: arbiters of cell survival. Science 281:1322.
40. Green, D. R., and J. C. Reed. 1998. Mitochondria and apoptosis. Science 281: 1309.
41. Kroemer, G. 1997. The proto-oncogene bcl-2 and its role in regulating apoptosis. Nat. Med. 3:614.
42. Boise, L. H., A. R. Gottschalk, J. Quintans, and C. B. Thompson. 1995. Bcl-2 and Bcl-2-related proteins in apoptosis regulation. Curr. Top. Microbiol. Immunol. 200:101.
43. Nagata, S. 1997. Apoptosis by death factor. Cell 88:355.
44. Miles, S. A. 1996. Pathogenesis of AIDS-related Kaposi's sarcoma: evidence of a viral etiology. Hematol. Oncol. Clin. North Am. 10:1011.
45. Miles, S. A., O. Martinez-Maza, A. Rezai, L. Magpantay, T. Kishimoto, S. Nakamura, S. F. Radka, and P. S. Linsley. 1992. Oncostain M as a potent mitogen for AIDS-Kaposi's sarcoma-derived cells. Science 255:1432.
46. Murakami-Mori, K., T. Taga, T. Kishimoto, and S. Nakamura. 1996. The soluble form of the IL-6 receptor (sIL-6Rα) is a potent growth factor for AIDS-associated Kaposi's sarcoma (KS) cells: the soluble form of gp130 is antagonistic for sIL-6Rα-induced AIDS-KS cell growth. Int. Immunol. 8:595.
47. Murakami-Mori, K., S. Mori, T. Taga, T. Kishimoto, and S. Nakamura. 1997. Enhancement of gp130-mediated tyrosine phosphorylation of STAT3 and its DNA-binding activity in dexamethasone-treated AIDS-associated Kaposi's sarcoma cells. J. Immunol. 158:551.
48. Real, F. X., S. E. Krown, and B. Koziner. 1986. Steroid-related development of Kaposi's sarcoma in a homosexual man with Burkitt's lymphoma. Am. J. Med. 80:119.
49. Gill, P. S., C. Loureiro, M. Bernstein-Singer, M. U. Rarick, F. Sattler, and A. M. Levine. 1989. Clinical effect of glucocorticoids on Kaposi's sarcoma related to the acquired immune deficiency syndrome (AIDS). Ann. Intern. Med. 110:937.
50. Griffith, T. S., W. A. Chin, G. C. Jackson, D. H. Lynch, and M. Z. Kubin. 1998. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J. Immunol. 161:2833.
51. Ahmad, M., S. M. Srinivasula, L. Wang, R. V. Talanian, G. Litwack, T. Femandes-Alnemri, and E. S. Alnemri. 1997. CRADD, a novel human apoptotic adaptor molecule for caspase-2, and FasL/tumor necrosis factor-receptor-interacting protein RIP. Cancer Res. 57:615.
52. Duan, H., and V. M. Dixit. 1997. RAIDD is a new "death" adaptor molecule. Nature 385:86.
53. Yeh, W.-C., J. L. de la Pompa, M. E. McCurrach, H.-B. Shu, A. J. Elia, A. Shahinian, M. Ng, A. Wakeham, W. Khoo, K. Mitchell, et al. 1998. FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science 279:195.
54. Wajant, H., F.-J. Johannes, E. Haas, K. Siemienski, R. Schwenzer, G. Schubert, T. Weiss, M. Grell, and P. Scheurich. 1998. Dominant-negative FADD inhibits TNFR60-, Fas/Apo-1- and TRAIL/Apo-2-mediated cell death but not gene induction. Curr. Biol. 8:113.
55. L, and Apaf-1 form a ternary complex. J. Biol. Chem. 273:584.
56. 2 in breast carcinoma cells. Oncogene 10:2297.
57. L can inhibit apoptosis in cells that have undergone Fas-induced protease activation. Proc. Natl. Acad. Sci. USA 94: 3795.
58. Scaffidi, C., S. Fulda, A. Srinivasan, C. Friesen, F. Li, K. J. Tomaselli, K.-M. Debatin, P. H. Krammer, and M. E. Peter. 1998. Two CD95 (Apo-1/Fas) signaling pathways. EMBO J. 17:1675.
59. Thomas, W. D., and P. Hersey. 1998. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J. Immunol. 161:2195.
60. Sheikh, M. S., T. F. Burns, Y. Huang, G. S. Wu, S. Amundson, K. S. Brooks, A. J. Fornace, Jr, and W. S. El-Deiry. 1998. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor α. Cancer Res. 58:159.